The aim of the study was to evaluate the effect of risedronate on bone mineral density (BMD) and bone turnover markers in HIV-infected osteoporotic males, according to their gonadal status. HIV patients were followed up for 24 months and divided into two groups: patients with osteoporosis or osteopenia with fractures (group A, n = 20) and those without (group B, n = 21). Group A and B were further divided according to the presence of reduced androgenizations. Both groups were treated with cholecalciferol 800 I.U. and calcium (Ca) 1,000 mg orally every day for the first 12 months. Risedronate 75 mg for two consecutive days a month orally was then added in group A, for another 12 months. Group B continued treatment with Ca and vitamin D. Every 6 months each patient underwent biochemical evaluation, and BMD measurement. A significant increase in lumbar BMD was observed in HIV males with adequate androgenization after 12 months of risedronate treatment in group A together with a reduction of bone turnover markers. BMD remained stable with a concomitant significant slight reduction of bone turnover markers in group B. Risedronate increased BMD and reduced bone turnover markers to a greater extent in patients with adequate androgenization compared to osteoporotic HIV males with symptomatic hypoandrogenization. © 2014 Springer Science+Business Media New York.

Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study / Pepe, Jessica; Isidori, Andrea; Falciano, Mario; G., Iaiani; Salotti, Alessandra; Diacinti, Daniele; R., Del Fiacco; Sbardella, Emilia; Cipriani, Cristiana; Piemonte, Sara; Raimo, Orlando; P., Biondi; Biamonte, Federica; Lenzi, Andrea; Minisola, Salvatore. - In: ENDOCRINE. - ISSN 1355-008X. - STAMPA. - 47:2(2014), pp. 456-462. [10.1007/s12020-014-0349-0]

Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study

PEPE, JESSICA;ISIDORI, Andrea;FALCIANO, Mario;SALOTTI, Alessandra;DIACINTI, Daniele;SBARDELLA, EMILIA;CIPRIANI, Cristiana;PIEMONTE, SARA;RAIMO, ORLANDO;BIAMONTE, FEDERICA;LENZI, Andrea;MINISOLA, Salvatore
2014

Abstract

The aim of the study was to evaluate the effect of risedronate on bone mineral density (BMD) and bone turnover markers in HIV-infected osteoporotic males, according to their gonadal status. HIV patients were followed up for 24 months and divided into two groups: patients with osteoporosis or osteopenia with fractures (group A, n = 20) and those without (group B, n = 21). Group A and B were further divided according to the presence of reduced androgenizations. Both groups were treated with cholecalciferol 800 I.U. and calcium (Ca) 1,000 mg orally every day for the first 12 months. Risedronate 75 mg for two consecutive days a month orally was then added in group A, for another 12 months. Group B continued treatment with Ca and vitamin D. Every 6 months each patient underwent biochemical evaluation, and BMD measurement. A significant increase in lumbar BMD was observed in HIV males with adequate androgenization after 12 months of risedronate treatment in group A together with a reduction of bone turnover markers. BMD remained stable with a concomitant significant slight reduction of bone turnover markers in group B. Risedronate increased BMD and reduced bone turnover markers to a greater extent in patients with adequate androgenization compared to osteoporotic HIV males with symptomatic hypoandrogenization. © 2014 Springer Science+Business Media New York.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/618813
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact